|1.||Walker, Bruce D: 14 articles (12/2014 - 12/2003)|
|2.||Allen, Todd M: 9 articles (01/2013 - 12/2003)|
|3.||Altfeld, Marcus: 8 articles (01/2015 - 12/2003)|
|4.||Blankson, Joel N: 7 articles (03/2014 - 05/2006)|
|5.||Mallal, Simon: 6 articles (01/2015 - 06/2005)|
|6.||Phillips, Elizabeth: 5 articles (01/2015 - 01/2014)|
|7.||Siliciano, Robert F: 5 articles (03/2014 - 05/2006)|
|8.||Routy, Jean-Pierre: 5 articles (01/2014 - 07/2007)|
|9.||Brander, Christian: 5 articles (12/2012 - 08/2005)|
|10.||Pirmohamed, Munir: 4 articles (08/2015 - 01/2012)|
11/01/2011 - "These findings are reminiscent of the selection of deleterious CTL escape and compensatory mutations by HLA-B57 in HIV-1 infection and, thus, may suggest a common mechanism by which alleles like HLA-B57 mediate protection against these highly variable pathogens."
12/15/2011 - "The MHC class I molecule Mamu-B*17 has been associated with elite control of SIV infection in rhesus macaques, akin to the protective effects described for HLA-B*57 in HIV-infected individuals. "
02/01/2011 - "Our data indicate a role of HLA-B 57-restricted CD8(+) T-cell responses in mediating spontaneous clearance and evolution in HCV infection, and viral strains containing epitope variants that are less recognized abrogate the protective effects of HLA-B 57. "
01/01/2015 - "We focused on HLA-B*57:01 and its interaction with KIR3DL1, which has been shown to play a critical role in determining the progression of a number of human diseases, including human immunodeficiency virus-1 infection. "
01/01/2015 - "At recruitment the proportion of patients carrying a HLA-B*57 allele differed between HIV- (12.9%) and HCV-infection (4.2%). "
05/01/2014 - "HLA-B*57:01 and HLA-B*57:03, the most prevalent HLA-B*57 subtypes in Caucasian and African populations, respectively, are the HLA alleles most protective against HIV disease progression. "
11/01/2013 - "However, there is considerable heterogeneity in HIV-1 disease progression rates among HLA-B*57-positive subjects, suggesting that additional factors may help to contain viral replication. "
01/01/2014 - "Fitness costs and slower disease progression are associated with a cytolytic T lymphocyte (CTL) escape mutation T242N in Gag in HIV-1-infected individuals carrying HLA-B*57/5801 alleles. "
11/01/2013 - "The HLA-B*57 allele is strongly associated with viremic suppression and slower disease progression. "
01/01/2013 - "Although virus isolates from HLA-B*57/58:01 individuals contained multiple CTL escape mutations, these escape mutations were not associated with disease progression. "
|3.||HIV Infections (HIV Infection)
01/01/2015 - "HLA class I alleles, in particular HLA-B*57, constitute the most consistent host factor determining outcomes in untreated HCV- and HIV-infection. "
06/01/2014 - "In Zambia, ReA is associated with the HLA-B*57:03 allele, which is paradoxically also associated with slow progression of HIV infection. "
01/01/2014 - "The HLA-B*57 allele, which is associated with a better clinical outcome in HIV infection, is overrepresented in HIC. "
01/01/2012 - "The genetic polymorphism that has the greatest impact on immune control of human immunodeficiency virus (HIV) infection is expression of HLA-B*57. "
12/01/2008 - "[Carrying certain KIR3DL1 alleles with HLA-B*57 is associated with protection from HIV infection]."
|4.||Acquired Immunodeficiency Syndrome (AIDS)
01/01/2005 - "In Caucasoids and Africans, HLA-B57 and related alleles of the B58 supertype associate with low viraemia, delayed onset of AIDS and, possibly, cytotoxic T lymphocyte (CTL)-driven attenuation of HIV-1. "
10/01/2013 - "HLA-B*57 is strongly associated with immune control of HIV and delayed AIDS progression. "
06/01/2011 - "The protective effect of HLA-B*57 on slow progression to AIDS and low VL may be mediated through its interaction with KIR3DL1 alleles to educate NK cells for potent activity upon stimulation."
06/01/2011 - "Carriage of the natural killer (NK) receptor genotype KIR3DL1*h/*y with its HLA-B*57 ligand (*h/*y+B*57) is associated with slow time to AIDS and low viral load (VL). "
01/01/2014 - "Carriage of the genetic combination encoding a high expression inhibitory Killer Immunoglobulin-like Receptor (KIR)3DL1 with its ligand, HLA-B*57 (*h/*y+B*57) is associated with slower time to AIDS and better HIV viral load control than being a Bw6 homozygote (Bw6hmz). "
12/01/2012 - "Why the ABC hypersensitivity syndrome is only seen in HLA-B57:01-expressing subjects and what the precise mechanisms underlying this intolerance are remain however controversial. "
05/01/2014 - "To determine diagnostic accuracy of HLA-B*57:01 testing for prediction of abacavir-induced hypersensitivity and to quantify the clinical benefit of pretreatment screening through a meta-analytic review of published studies. "
07/01/2011 - "The usefulness of HLA-B57 screening for prediction of abacavir hypersensitivity was shown in three independent laboratories, including confirmation of the mAb sensitivity and specificity in a cohort of patients enrolled in the PREDICT-1 trial. "
03/30/2002 - "The lower sensitivity of HLA-B57 for predicting hypersensitivity to abacavir identified in this study compared with a previous report highlights that predictive values for markers will vary across populations. "
10/01/2015 - "Pharmacogenetics of abacavir hypersensitivity: A systematic review and meta-analysis of the association with HLA-B*57:01."
|1.||HLA-B27 Antigen (HLA B27 Antigen)
|2.||HLA Antigens (Human Leukocyte Antigens)
|5.||HLA-B Antigens (HLA-B)
|8.||RNA-Directed DNA Polymerase (Reverse Transcriptase)
|9.||Proteins (Proteins, Gene)
|1.||Highly Active Antiretroviral Therapy (HAART)